Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Hillevax Inc (HLVX)

Hillevax Inc (HLVX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
3 IPO Stocks That You Want to Own Motley Fool - Sun Sep 25, 2022

This down market is giving us some really intriguing stocks at cheap prices.

AMLX : 3.10 (+7.64%)
HLVX : 1.8000 (-0.55%)
DCGO : 3.48 (-3.33%)
TAK : 14.80 (-0.87%)
HilleVax Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress Globe Newswire - Wed Aug 10, 2022

BOSTON, Aug. 10, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and...

HLVX : 1.8000 (-0.55%)
HilleVax Announces Results from 5-Year Clinical Study Supporting Long-Term Immunogenicity of HIL-214 Norovirus Vaccine Candidate Globe Newswire - Wed Jul 20, 2022

Pan-Ig and HBGA blocking antibody responses persisted to year 5 No adverse events deemed related to HIL-214 BOSTON, July 20, 2022 (GLOBE NEWSWIRE)...

HLVX : 1.8000 (-0.55%)
HilleVax Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress Globe Newswire - Wed Jun 8, 2022

Initiated Phase 2b Clinical Trial of HIL-214 Vaccine Candidate for the Prevention of Norovirus-Related Acute Gastroenteritis in Infants (NOR-212) ...

HLVX : 1.8000 (-0.55%)
HilleVax Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares Globe Newswire - Tue May 3, 2022

BOSTON, May 03, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and...

HLVX : 1.8000 (-0.55%)
Stocks-Money-Rates - Chart with Stocks and Commodities
Stock Market This Week: Five Themes To Watch Barchart - Sun May 1, 2022

Following a volatile series of sessions, investors are entering the month of May with several reasons to be cautious.

HLVX : 1.8000 (-0.55%)
MPC : 164.39 (-1.18%)
VWAGY : 10.6900 (-2.20%)
CNK : 28.32 (-0.04%)

Barchart Exclusives

3 Dividend Kings With Unstoppable Dividend Growth Potential Barchart - Fri Sep 20, 6:00PM CDT
Discover three quality companies with healthy financials, low dividend payout ratios, and a history of incredible dividend growth. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot